The researchers also used blood vessel and kidney organoids to demonstrate that SARS-CoV-2 can directly infect and multiply within these tissues, a possible cause of the multi-organ failures and cardiovascular damage seen in severe COVID-19 cases.
"We are enthusiastic our results have effects for the advancement of an unique drug for the treatment of this unmatched pandemic", stated Josef Penninger, from the College of British Columbia in Canada.
Labs at Scripps Research and throughout the world are now seeking antibodies, via blood donations, from people who have recovered from COVID-19 for further studies along these lines. The workforce's findings had been reported Thursday in eBioMedicine, which is printed by The Lancet.
Scientists across the globe are racing to develop a vaccine to protect against coronavirus, which has infected more than a confirmed 950,000 people worldwide and claimed almost 50,000 lives. "Haibo Zhang and Art Slutsky from Toronto and especially Ali Mirazimi's infectious biology team in Sweden, who have been working tirelessly day and night for weeks to better understand the pathology of this disease and to provide breakthrough therapeutic options".
The study, posted on April 2, focuses on a protein found on the surface of human cells. Art Slutsky, also a scientist at Toronto's Keenan Research Centre for Biomedical Science at St. Michael's Hospital.
The WHO says masks should be worn by anyone with symptoms such as cough or fever, or anyone caring for a confirmed or suspected COVID-19 case, but does not advise healthy people to wear them in everyday situations.
The team will be applying for an investigational new drug approval from the US Food and Drug Administration to start human clinical trials in the next few months - but this is just the beginning. Núria Montserrat of the Institute for Bioengineering in Catalonia, Spain. In the next phase of testing, this vaccine will be tried on humans.
Despite the slight difference between the two coronaviruses, the antibody binds much less tightly to SARS-CoV-2 than it does to the SARS virus, and can not neutralize SARS-CoV-2 in lab dish tests as it does SARS-CoV.
Many strategies are being deployed to rapidly uncover targetable mechanisms of infection for SARS-CoV-2, and Hoffman et al. exploit our understanding and immunological experience with SARS-CoV in our global race to understand, mitigate, and eventually prevent COVID-19.
"Now we know that a soluble form of ACE2 could be indeed a very rational therapy that specifically targets the gate the virus must take to infect us".
The research suggests that COVID-19 may be susceptible to certain drugs and is crucial in tracking it's spread.